Antagonising EP1 and EP2 receptors reveal that the TP receptor mediates a component of antigen-induced contraction of the guinea pig trachea

Bitter taste receptor agonists mediate relaxation of human and rodent vascular smooth muscle

“…To further evaluate the potential of TAS2R agonists in settings of relevance to asthma, the effects of chloroquine and denatonium were examined following antigen-induced contractions of the guinea pig trachea. This contraction is similar to indirect bronchoconstriction in humans and is caused by the release of spasmogenic mast cell mediators [131]. Furthermore, chloroquine, denatonium, dextromethorphan, noscapine and quinine did not induce baseline contractions in guinea pig tracheal rings.…”

Prostaglandin EP2 receptor: Novel therapeutic target for human cancers (Review)

“…The non-selective EP receptor antagonist AH6809 has been widely applied to explore the roles of PGE2/EP2 signaling under normal and pathological conditions (109). Although AH6809 acts as an antagonist of EP2, it may also serve as an antagonist of EP1 and dP1 (110); it is neither selective nor potent, and is therefore unsuitable for in vivo studies (111). However, it has been demonstrated that allosteric potentiators and selective antagonists of the EP2 receptor with non-prostanoid structure can explain the physiological functions of prostaglandin receptors (112).…”

Mannitol triggers mast cell–dependent contractions of human small bronchi and prostacyclin bronchoprotection

“…The phenomenon that more powerful contractions of main agonists (CysLTs in this case) can mask responses to comediators that are less potent has been described for mast cell-dependent contractions in other models. 26 Thus the complex activation of several contractile receptors during hyperosmolar exposure in bronchial segments might be similar in patients with EIB and support the need of treatment with a combination of receptor antagonists. The approach to inhibit all 3 main classes of mast cell mediators (CysLTs, histamine, and PGD 2 ) was demonstrated to be effective here but has not yet been tested in asthmatic patients either for EIB or allergen-induced bronchoconstriction.…”